ArticleFrontiers in public health2026
National divergence in cardio-kidney-metabolic syndrome burden and implications for health policy: a global burden of disease analysis with projections to 2050.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The co-occurring epidemics of diabetes and obesity have increased the prevalence of Cardio-Kidney-Metabolic (CKM) syndrome. Comparative studies on long-term trends of its three core components [ischemic heart disease (IHD), diabetic kidney disease (DKD), non-alcoholic fatty liver disease (NAFLD)] across major countries are still limited. Methods: We analyzed age-standardized disability-adjusted life year (DALY) rates of IHD, DKD, and NAFLD attributable to high fasting plasma glucose (HFPG) from 1990 to 2021 among seven representative middle-and high-income countries using Global Burden of Disease 2021 data. We assessed temporal trends, conducted hierarchical clustering, and projected burdens to 2050. Results: We found substantial cross-country heterogeneity. From 1990 to 2021, IHD burden decreased significantly in the United States and Japan, while trends in China and India showed high uncertainty (coefficients of variation >100%) and should be interpreted with caution. DKD burden increased in Saudi Arabia and the United States but decreased in China. NAFLD burden increased in Saudi Arabia, the United States, India, and South Africa, while declining in China and Japan. Cluster analysis identified three patterns: "High IHD Burden" (India), "High Metabolic Burden" (Saudi Arabia), and "Low-Moderate Burden" (other countries). HFPG was associated with the largest share of DKD burden (Population Attributable Fraction [PAF] >80%) and a substantially smaller share of NAFLD burden (PAF <11%).Projections to 2050 show a sharp rise in DKD in the United States and India, together with increasing NAFLD burden, indicating a shift toward metabolic organ damage. Conclusions: The burden of CKM syndrome is substantial and dynamic, with marked cross-country differences. These findings support the need for integrated, multi-organ risk management strategies for metabolic disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.